trending Market Intelligence /marketintelligence/en/news-insights/trending/ZzxHUOA4b7yKIH6BrGIq3A2 content esgSubNav
In This List

AstraZeneca sees no risks after disclosure of falsified cancer drug data

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


AstraZeneca sees no risks after disclosure of falsified cancer drug data

AstraZeneca PLC said a preclinical data set from one early-stage study supporting the development of acalabrutinib for cancer were falsified, adding that there are no risks for patients.

The company said a former Acerta Pharma employee acted alone to falsify the preclinical data set provided through external collaborations, but the "isolated issue" had no effect on the integrity of the drug.

The "data integrity issue" pre-dated AstraZeneca's $4 billion investment in Acerta Pharma in 2015.

In August, the U.S. Food and Drug Administration granted breakthrough therapy designation to acalabrutinib to treat patients with mantle cell lymphoma, a rare type of blood cancer.